Zai Lab/$ZLAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
Ticker
$ZLAB
Sector
Primary listing
Employees
1,869
Headquarters
Website
Zai Lab Metrics
BasicAdvanced
$2.1B
-
-$1.92
0.85
-
Price and volume
Market cap
$2.1B
Beta
0.85
52-week high
$44.34
52-week low
$18.78
Average daily volume
946K
Financial strength
Current ratio
2.871
Quick ratio
2.285
Long term debt to equity
1.426
Total debt to equity
28.866
Interest coverage (TTM)
-47.96%
Profitability
EBITDA (TTM)
-213.793
Gross margin (TTM)
9.18%
Net profit margin (TTM)
-46.83%
Operating margin (TTM)
-51.61%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
-13.29%
Return on equity (TTM)
-28.97%
Valuation
Price to revenue (TTM)
4.639
Price to book
2.77
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
-9.737
Free cash flow yield (TTM)
-10.27%
Free cash flow per share (TTM)
-1.956
Growth
Revenue change (TTM)
24.14%
Earnings per share change (TTM)
-30.76%
3-year revenue growth (CAGR)
30.96%
3-year earnings per share growth (CAGR)
-32.32%
What the Analysts think about Zai Lab
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Zai Lab Financial Performance
Revenues and expenses
Zai Lab Earnings Performance
Company profitability
Zai Lab News
AllArticlesVideos
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
Business Wire·1 day ago
Zai Lab Announces Updates to China's National Reimbursement Drug List
Business Wire·3 days ago
Zai Lab Announces Participation in Investor Conferences in November and December 2025
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $2.1B as of December 09, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of December 09, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of December 09, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.